Lingohr Asset Management GmbH Has $6.30 Million Holdings in Gilead Sciences, Inc. $GILD

Lingohr Asset Management GmbH boosted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 742.2% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 56,737 shares of the biopharmaceutical company’s stock after buying an additional 50,000 shares during the period. Gilead Sciences makes up approximately 1.5% of Lingohr Asset Management GmbH’s investment portfolio, making the stock its 25th largest position. Lingohr Asset Management GmbH’s holdings in Gilead Sciences were worth $6,298,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Csenge Advisory Group boosted its holdings in Gilead Sciences by 319.0% in the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares in the last quarter. Railway Pension Investments Ltd boosted its stake in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after purchasing an additional 42,200 shares during the period. TriaGen Wealth Management LLC bought a new stake in shares of Gilead Sciences in the third quarter valued at approximately $1,274,000. iA Global Asset Management Inc. boosted its holdings in Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after purchasing an additional 23,046 shares during the period. Finally, Invesco Ltd. lifted its stake in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $141.95 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock has a 50 day moving average price of $125.36 and a 200 day moving average price of $119.59. The stock has a market capitalization of $176.11 billion, a PE ratio of 22.01, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $142.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the company posted $2.02 earnings per share. Gilead Sciences’s quarterly revenue was up 3.0% on a year-over-year basis. Analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the completion of the sale, the chief executive officer owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. This trade represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 257,397 shares of company stock worth $33,385,512. Insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Wolfe Research lifted their target price on shares of Gilead Sciences from $150.00 to $155.00 and gave the company an “outperform” rating in a research report on Wednesday. Needham & Company LLC increased their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Citigroup increased their price target on shares of Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a research note on Tuesday. Wells Fargo & Company raised their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $100.00 to $103.00 and gave the stock a “sector perform” rating in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $136.36.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.